Ahmad (Nasser) Salameh

Ahmad (Nasser) Salameh is an Associate Director of Research & Development at ImmunoGenesis, Inc. with a background as a Senior Principal Scientist at AgilVax and The University of Texas Health Science Center at Houston. Ahmad (Nasser) has a strong research interest in developing humanized antibodies for targeting therapy in cancer and identifying genes involved in resistance to antibodies targeting therapy against EGFR, HER2, and HER3 in cancer. Their previous experience includes roles at MD Anderson Cancer Center, Università degli Studi di Siena, and ETH Zürich. Ahmad (Nasser) holds a PhD in Biotechnology from Università di Siena and a Master of Science in Biological Sciences & Molecular Biology from Università degli Studi di Padova.